Document Detail


Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the United States, 2000-2010.
MedLine Citation:
PMID:  23446495     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We assessed laboratory monitoring after combination antiretroviral therapy initiation among 3678 patients in a large US multisite clinical cohort, censoring participants at last clinic visit, combination antiretroviral therapy change, or 3 years. Median days (interquartile range) to first hematologic, hepatic, renal, and lipid tests were 30 (18-53), 31 (19-56), 33 (20-59), and 350 (96-1106), respectively. At 1 year, approximately 80% received more than 2 hematologic, hepatic, and renal tests consistent with guidelines. However, only 40% received 1 or more lipid tests. Monitoring was more frequent in specific subgroups, likely reflecting better clinic attendance or clinician perception of higher susceptibility to toxicities.
Authors:
Elizabeth L Yanik; Sonia Napravnik; Patrick Ryscavage; Joseph J Eron; Susan L Koletar; Richard D Moore; Anne Zinski; Stephen R Cole; Peter Hunt; Heidi M Crane; James Kahn; William C Mathews; Kenneth H Mayer; Babafemi O Taiwo;
Related Documents :
2128365 - Microbiological study of enterococcus faecium sf68: post-antibiotic effect and growth c...
24359605 - Clinical neuropathology practice news 1-2014: pyrosequencing meets clinical and analyti...
24098705 - Field evaluation of a prototype paper-based point-of-care fingerstick transaminase test.
24936995 - In vivo cardiovascular effects of the new atypical neuroleptic sertindole.
6868345 - Preliminary observations on the presence of visna-maedi in italy.
7413595 - The effects of exogenous steroidal hormones on the testes of quail from selected high a...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  63     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-13     Completed Date:  2013-07-08     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  216-20     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alanine Transaminase / blood
Anti-HIV Agents / adverse effects*,  therapeutic use
Antiretroviral Therapy, Highly Active*
Aspartate Aminotransferases / blood
Bilirubin / blood
Blood Cell Count
Cohort Studies
Creatinine / blood
Drug Monitoring*
Female
HIV Infections / drug therapy*,  metabolism
Hematologic Tests*
Humans
Kidney / drug effects*
Lipids / blood*
Liver / drug effects*
Male
United States
Grant Support
ID/Acronym/Agency:
5T32-AI007001-35/AI/NIAID NIH HHS; P30 AI027767/AI/NIAID NIH HHS; P30 AI050410/AI/NIAID NIH HHS; P30-AI50410/AI/NIAID NIH HHS; R01-HS018731/HS/AHRQ HHS; R24 AI067039/AI/NIAID NIH HHS; R24-AI067039/AI/NIAID NIH HHS; T32 AI007001/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Lipids; AYI8EX34EU/Creatinine; EC 2.6.1.1/Aspartate Aminotransferases; EC 2.6.1.2/Alanine Transaminase; RFM9X3LJ49/Bilirubin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Spirituality, Religiosity, Depression, Anxiety, and Drug-Use Consequences During Methadone Maintenan...
Next Document:  Effect of the levonorgestrel intrauterine device on genital HIV-1 RNA shedding among HIV-1-infected ...